CD123 binding agents and uses thereof
First Claim
1. An isolated antibody, or an antigen-binding fragment thereof, that binds immunospecifically to Interleukin-3 Receptor alpha (IL3-Rα
- ) SP2 and IL3-Rα
SP1 comprising a heavy chain and a light chain having;
a. a heavy chain CDR1 having the amino acid sequence of SEQ ID NO;
012, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO;
013, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO;
014, a light chain CDR1 having the amino acid sequence of SEQ ID NO;
015, a light chain CDR2 having the amino acid sequence of SEQ ID NO;
016, and a light chain CDR3 having the amino acid sequence of SEQ ID NO;
017;
orb. a heavy chain CDR1 having the amino acid sequence of SEQ ID NO;
051, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO;
052, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO;
053, a light chain CDR1 having the amino acid sequence of SEQ ID NO;
024, a light chain CDR2 having the amino acid sequence of SEQ ID NO;
025, and a light chain CDR3 having the amino acid sequence of SEQ ID NO;
054.
1 Assignment
0 Petitions
Accused Products
Abstract
Provided herein are antibodies that immunospecifically bind to CD123. Also described are related polynucleotides capable of encoding the provided CD123-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor CD123-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with CD123-expressing cancer and thus may be amenable to treatment with a CD123-specific anti-cancer therapeutic, such as the multispecific antibodies against CD123 and CD3 described herein.
-
Citations
20 Claims
-
1. An isolated antibody, or an antigen-binding fragment thereof, that binds immunospecifically to Interleukin-3 Receptor alpha (IL3-Rα
- ) SP2 and IL3-Rα
SP1 comprising a heavy chain and a light chain having;a. a heavy chain CDR1 having the amino acid sequence of SEQ ID NO;
012, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO;
013, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO;
014, a light chain CDR1 having the amino acid sequence of SEQ ID NO;
015, a light chain CDR2 having the amino acid sequence of SEQ ID NO;
016, and a light chain CDR3 having the amino acid sequence of SEQ ID NO;
017;
orb. a heavy chain CDR1 having the amino acid sequence of SEQ ID NO;
051, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO;
052, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO;
053, a light chain CDR1 having the amino acid sequence of SEQ ID NO;
024, a light chain CDR2 having the amino acid sequence of SEQ ID NO;
025, and a light chain CDR3 having the amino acid sequence of SEQ ID NO;
054. - View Dependent Claims (2, 3, 4, 5, 6, 19)
- ) SP2 and IL3-Rα
-
7. An isolated bispecific antibody or antigen-binding fragment comprising a first heavy chain (HC1), a second heavy chain (HC2), first light chain (LC1) and a second light chain (LC2), such that the HC1 and the LC1 pair to form a first antigen-binding site that immunospecifically binds IL3-Rα
- , and the HC2 and the LC2 pair to form a second antigen-binding site that immunospecifically binds CD3, or an IL3-Rα and
CD3-bispecific binding fragment thereof, wherein;i) HC1 and LC1 comprise either of the following pairs; a. SEQ ID NO;
203 and SEQ ID NO;
204, orb. SEQ ID NO;
205 and SEQ ID NO;
206, respectively; andii) HC2 and LC2 comprise any one of the following pairs; a. SEQ ID NO;
193 and SEQ ID NO;
194,b. SEQ ID NO;
195 and SEQ ID NO;
196,c. SEQ ID NO;
197 and SEQ ID NO;
198,d. SEQ ID NO;
199 and SEQ ID NO;
200, ore. SEQ ID NO;
201 and SEQ ID NO;
202, respectively. - View Dependent Claims (8, 9, 10, 11, 12, 13, 14, 15, 20)
- , and the HC2 and the LC2 pair to form a second antigen-binding site that immunospecifically binds CD3, or an IL3-Rα and
-
16. A bispecific antibody or antigen-binding fragment comprising:
-
a. a paired heavy and light chain that immunospecifically binds CD3, wherein said heavy chain comprises SEQ ID NO;
184 and said light chain comprises SEQ ID NO;
190, andb. a paired heavy and light chain that immunospecifically binds IL3-Rα
, whereini. said heavy chain comprises SEQ ID NO;
120 and said light chain comprises SEQ ID NO;
165, orii. said heavy chain comprises SEQ ID NO;
136 and said light chain comprises SEQ ID NO;
168. - View Dependent Claims (17, 18)
-
Specification